Raymond James Maintains Their Buy Rating on TG Therapeutics

By Austin Angelo

Raymond James analyst Reni Benjamin maintained a Buy rating on TG Therapeutics (NASDAQ: TGTX) yesterday. The company’s shares closed yesterday at $14.35.

Benjamin observed:

“We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS).”

According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 2.1% and a 43.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Invivo Therapeutics Holdings, Adaptimmune Therapeutics, and Voyager Therapeutics Inc.

Currently, the analyst consensus on TG Therapeutics is Strong Buy and the average price target is $29.33, representing a 104.4% upside.

In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $38 price target.

The company has a one-year high of $17.35 and a one-year low of $7.25. Currently, TG Therapeutics has an average volume of 1.51M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H.